Name: Latest research reports of Ajanta Pharma Ltd. authored by ICICI Direct and published by - Trendlyne research reports.
Item: Ajanta Pharma Ltd.
Rating: 5
Author: ICICI Direct

Summary	Date	Stock	Author	LTP	Target	Price at reco (Change since reco%)	Upside(%)	Type	Report	Discuss
	14 Sep 2025	Ajanta Pharma	Consensus Share Price Target	2579.10	3008.33	-	16.64	buy	pdf Detailed Estimates
	02 Feb 2023	Ajanta Pharma	ICICI Direct Target	2579.10	1385.00	1191.50 (116.46%)	Target met	Buy	pdf post cache	Broker Report Ajanta Pharmaceuticals ICICI Direct pdf Copy Link Share on Share on Share on Share on Alert
	04 Nov 2022	Ajanta Pharma	ICICI Direct Target	2579.10	1505.00	1256.20 (105.31%)	Target met	Buy	pdf post cache	Broker Report Ajanta Pharmaceuticals ICICI Direct pdf Copy Link Share on Share on Share on Share on Alert
	04 Nov 2022	Ajanta Pharma	BOB Capital Markets Ltd.	2579.10	1470.00	1256.20 (105.31%)	Target met	Hold	pdf post cache	Broker Report Ajanta Pharma (HOLD): No respite from margin pressure; cut to HOLD BOB Capital Markets Ltd. Q2 revenue growth muted at 6% YoY as lower Africa/US sales offset a strong uptick in India/Asia business pdf Copy Link Share on Share on Share on Share on Alert
	04 Nov 2022	Ajanta Pharma	Motilal Oswal	2579.10	1560.00	1256.20 (105.31%)	Target met	Buy	pdf post cache	Broker Report India and Asia drives, while the US and Africa drag earnings Motilal Oswal pdf Copy Link Share on Share on Share on Share on Alert
	29 Jul 2022	Ajanta Pharma	ICICI Direct	2579.10	1495.00	1278.60 (101.71%)	Target met	Buy	pdf post cache	Broker Report Ajanta Pharmaceuticals ICICI Direct pdf Copy Link Share on Share on Share on Share on Alert
	22 Jun 2022	Ajanta Pharma	ICICI Direct	2579.10	1305.00	1214.80 (112.31%)	Pre-Bonus/ Split	Hold	pdf post cache	Broker Report Ajanta Pharmaceuticals ICICI Direct pdf Copy Link Share on Share on Share on Share on Alert
	11 May 2022	Ajanta Pharma	ICICI Direct	2579.10	1955.00	1684.70 (53.09%)	Pre-Bonus/ Split	Buy	pdf post cache	Broker Report Ajanta Pharmaceuticals ICICI Direct pdf Copy Link Share on Share on Share on Share on Alert
	11 May 2022	Ajanta Pharma	BOB Capital Markets Ltd. Target	2579.10	2050.00	1684.70 (53.09%)	Pre-Bonus/ Split	Buy	pdf post cache	Broker Report Ajanta Pharma (BUY): Margin stress continues BOB Capital Markets Ltd. Q4 revenue 6% ahead of our estimate but margins disappointed with gross/EBITDA margin contraction of 530bps/1050bps YoY to ~72%/24% pdf Copy Link Share on Share on Share on Share on Alert
	22 Mar 2022	Ajanta Pharma	Motilal Oswal Target	2579.10	2500.00	1953.80 (32.00%)	Pre-Bonus/ Split	Buy	pdf post cache	Broker Report Robust outlook in the Branded Generics segment Motilal Oswal AJP delivered 13% sales CAGR from Dec'18 to Dec'21, led by steady traction in existing therapies and ramp-up in newly added therapies and the Trade Generics segment. It delivered a sales growth of 23% YoY to INR7.3b (30% of sales) in 9MFY22. With the easing of COVID-19 cases, doctor-patient connectivity has significantly improved, particularly in the Ophthalmology/Dermatology segment (39% of DF sales in 9MFY22). This bodes well for better growth prospects for AJP. This, along with enhanced marketing efforts in the Cardiology segment (~41% of DF sales in 9MFY22)... pdf Copy Link Share on Share on Share on Share on Alert
	02 Feb 2022	Ajanta Pharma	ICICI Securities Limited Target	2579.10	2605.00	2160.35 (19.38%)	Pre-Bonus/ Split	Buy	pdf post cache	Broker Report Ajanta Pharmaceuticals ICICI Securities Limited pdf Copy Link Share on Share on Share on Share on Alert
more loading

Ajanta Pharma Ltd. share price target

Ajanta Pharma Ltd. has an average share price target of 3022. The consensus estimate represents an upside of 17.17% from the last price of 2579.10. View 8 reports from 5 analysts offering long-term price targets for Ajanta Pharma Ltd..

Ajanta Pharmaceuticals

Ajanta Pharmaceuticals

Ajanta Pharma (HOLD): No respite from margin pressure; cut to HOLD

India and Asia drives, while the US and Africa drag earnings

Ajanta Pharmaceuticals

Ajanta Pharmaceuticals

Ajanta Pharmaceuticals

Ajanta Pharma (BUY): Margin stress continues

Robust outlook in the Branded Generics segment

Ajanta Pharmaceuticals

Advisor Screeners